<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345953</url>
  </required_header>
  <id_info>
    <org_study_id>P13-04 / BP 1.4979</org_study_id>
    <secondary_id>2013-004884-30</secondary_id>
    <nct_id>NCT03345953</nct_id>
  </id_info>
  <brief_title>Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome</brief_title>
  <acronym>P13-04</acronym>
  <official_title>Randomized Double Blind Parallel Groups Sequential, Placebo Controlled, Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (RLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Group Sequential Test multicenter, randomized, double blind, placebo controlled&#xD;
      phase II proof of concept trial with parallel groups to evaluate the efficacy and the safety&#xD;
      of BP1.4979 15mg BID compared to placebo in RLS patients during 2 weeks double blind&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study facing recruitment difficulties related to stringent eligibility criteria&#xD;
  </why_stopped>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Actual">April 29, 2020</completion_date>
  <primary_completion_date type="Actual">April 29, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Periodic Limb Movements per hour of Sleep (PLMS index)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measure of the difference from baseline (Randomization) to the end of the double blind treatment period in Periodic Limb Movements per hour of Sleep (PLMS index) measured with PolySomnoGraphy (PSG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IRLSRS (International Restless Legs Syndrome Rating Scale)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Difference in IRLSRS score measured at randomization and end double blind study.treatment period. IRLSRS is ranging from 0 (no symptoms) to 40 (very severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periodic Limb Movement during Wakefulness (PLMW)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Difference in PLMW measured at randomization and end double blind study treatment period. The PLMW will be measured during a Suggested Immobilization Test (1-hour test) to evaluate the limb movements during wakefulness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by AEs collection</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Safety and tolerability of BP 1.4979 as assessed by AEs collection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>BP 1.4979</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg tablet BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BP 1.4979</intervention_name>
    <description>Double blind versus placebo</description>
    <arm_group_label>BP 1.4979</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double blind versus placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females &gt; or = to 18 years&#xD;
&#xD;
          -  18 kg/m2 ≤ BMI ≤ 35 kg/m2&#xD;
&#xD;
          -  Diagnosis of idiopathic RLS based on medical history and the presence of the 5 RLS&#xD;
             diagnostic criteria and a normal clinical examination&#xD;
&#xD;
               1. An urge to move the legs usually but not always accompanied by, or felt to be&#xD;
                  caused by, uncomfortable and unpleasant sensations in the legs.&#xD;
&#xD;
               2. The urge to move the legs and any accompanying unpleasant sensations begin or&#xD;
                  worsen during periods of rest or inactivity such as lying down or sitting.&#xD;
&#xD;
               3. The urge to move the legs and any accompanying unpleasant sensations are&#xD;
                  partially or totally relieved by movement, such as walking or stretching, at&#xD;
                  least as long as the activity continues.&#xD;
&#xD;
               4. The urge to move the legs and any accompanying unpleasant sensations during rest&#xD;
                  or inactivity only occur or are worse in the evening or night than during the&#xD;
                  day.&#xD;
&#xD;
               5. The occurrence of the above features is not solely accounted for as symptoms&#xD;
                  primary to another medical or a behavioral condition.&#xD;
&#xD;
          -  The condition is not better explained by another current sleep disorder, medical or&#xD;
             neurological disorder, mental disorder, medication use, or substance use disorder.&#xD;
&#xD;
          -  RLS severity score &gt; or = to 21/40 and RLS occurring at least 3 times per week for 'de&#xD;
             novo' patients or after RLS treatment wash-out.&#xD;
&#xD;
          -  Periodic Limb Movements during Sleep index &gt; 15 for 'de novo' patients or after RLS&#xD;
             treatment wash out.&#xD;
&#xD;
          -  Not taking or accepting to discontinue drug therapy or medication for RLS,&#xD;
             antipsychotic medication, antidepressant including Selective Serotonin Reuptake&#xD;
             Inhibitors (SSRIs) prescribed for at least 5 half-lives prior to randomization (e.g.&#xD;
             fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram,&#xD;
             venlafaxine, milnacipran, duloxetine) and/or any other psychotropic medication&#xD;
             benzodiazepine and/or anticonvulsivants (gabapentine, pregabaline) prescribed to&#xD;
             relief RLS, for at least 5 half-lives prior to randomization and/or opiates.&#xD;
&#xD;
          -  Females of child-bearing potential must use a medically accepted effective method of&#xD;
             birth control, agree to continue this method for the duration of the study and be&#xD;
             negative to serum pregnancy test performed at the screening visit. Females should not&#xD;
             be breast-feeding. Males accept to use child conception prevention method for the&#xD;
             whole duration of the study&#xD;
&#xD;
          -  In the opinion of the investigator, the subject must have adequate support to comply&#xD;
             with the entire study requirements as described in the protocol (e.g. transportation&#xD;
             to and from trial site, self-rating scales, drug compliance, scheduled visits, etc).&#xD;
&#xD;
          -  Patient must have voluntarily expressed willingness to participate in this study,&#xD;
             understand protocol procedures and have signed and dated an informed consent prior to&#xD;
             beginning any protocol required procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant psychiatric illness (schizophrenia, bipolar disorder, severe&#xD;
             depression, dementia, obsessive compulsive disorder...) or mood disorder, assessed by&#xD;
             the Beck Depression Inventory (BDI) (exclusion if &gt; or = to 16 and/ or item G ≠ 0).&#xD;
&#xD;
          -  Abnormal neurological examination, history or presence of chronic pain other than that&#xD;
             associated with RLS. History of epilepsy or serious head injury. History of peripheral&#xD;
             neuropathy.&#xD;
&#xD;
          -  Clinically significant sleep apnea (Apnea Hypopnea Index &gt;15), narcolepsy, parasomnia&#xD;
             as an adult, circadian rhythm disorder, or secondary causes of RLS (e.g chronic renal&#xD;
             failure/hemodialysis).&#xD;
&#xD;
          -  Other active clinically significant illness, including unstable cardiovascular, or&#xD;
             neoplasic pathology which could interfere with the study conduct or counter-indicate&#xD;
             the study treatments, place the subject at risk during the trial or interfere with&#xD;
             study assessments or compromise the study participation.&#xD;
&#xD;
          -  Subject with a known history of long QTc syndrome (e.g. syncope or arrhythmia) or&#xD;
             presenting any significant serious abnormality of the ECG (e.g. recent myocardial&#xD;
             infarction), or QTcB interval strictly higher than 450 ms.&#xD;
&#xD;
          -  Subject with moderate hepatic impairment (transaminases &gt; 1.5 ULN) or with renal&#xD;
             impairment (creatinine clearance &lt; 90 mL/min) , or with any other significant&#xD;
             abnormality in the physical examination or clinical laboratory results (e.g positive&#xD;
             laboratory test for Hepatitis B surface antigen (HBsAg), or anti-HIV 1/2 or anti- HCV&#xD;
             antibodies).&#xD;
&#xD;
          -  Iron deficiency (ferritin &lt; 50 µg/l).&#xD;
&#xD;
          -  Known hypersensitivity to the tested treatment including active substance and&#xD;
             excipients.&#xD;
&#xD;
          -  Use of drugs likely to influence sleep architecture or motor manifestations during&#xD;
             sleep prior to randomization without an appropriate wash-out period. These include&#xD;
             neuroleptics, L-dopa, dopamine agonists, hypnotics, sedatives, anxiolytics,&#xD;
             antidepressants, anticonvulsants, psychostimulant medications, steroids in the&#xD;
             evening, barbiturates, benzodiazepine treatment and opiates to relief RLS.&#xD;
&#xD;
          -  Patient taking any prescription drug containing amphetamines.&#xD;
&#xD;
          -  Recent history (≤ 1 year) of alcohol or drug abuse, or current evidence of substance&#xD;
             dependence or abuse as defined by DSM-IV criteria (Gebauer L, LaBrie R et al. 2010).&#xD;
&#xD;
          -  Regular consumption of large amounts of xanthine-containing substances (i.e more than&#xD;
             5 cups of coffee or equivalent amounts of xanthine-containing substance per day).&#xD;
&#xD;
          -  Patient participating in another study and the use of any investigational therapy&#xD;
             within the 30 days prior to the entry in this study.&#xD;
&#xD;
          -  Patient without any medical care insurance.&#xD;
&#xD;
          -  Pregnant woman or a pregnancy detected with a positive serum pregnancy test performed&#xD;
             at the screening visit or lactating female.&#xD;
&#xD;
          -  Male patient who wants to conceive a child for the whole duration of the study.&#xD;
&#xD;
          -  Patient under guardianship who cannot provide consent on his own.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imad Ghorayeb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pellegrin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Neurophysiology Department - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

